How iPSC works
Reprogramming gives mature cells a pluripotent state. Researchers then direct differentiation toward specific cells for replacement therapies, disease models or drug testing. The cell source alone does not determine safety or approval status.
2026 clinical milestone
On 6 March 2026 Japan granted conditional, time-limited marketing approvals to Amchepry for Parkinson’s disease and ReHeart for severe heart failure due to ischaemic cardiomyopathy. Their use remains indication-specific, with conditions and ongoing evidence requirements.
Organoids and drug discovery
A February 2026 CiRA study used iPSC-derived lung organoids to model impaired repair in fibrosis and screen candidate compounds. This illustrates a research tool for understanding disease, not an approved treatment for lung fibrosis.
Japan
The Act on the Safety of Regenerative Medicine governs relevant research and medical practice; the PMD Act governs commercial products. A provision-plan procedure is not product marketing approval or an efficacy guarantee.
United States
Check the exact FDA authorisation and indication, or the applicable investigational pathway. Trial registration alone is not marketing approval. Recognised cell therapies do not authorise unrelated wellness claims.
China
State Council Order 818 took effect on 1 May 2026. Distinguish research filing, clinical-translation approval and drug marketing authorisation. Related research fees must not be charged to participants; approved clinical application follows the applicable charging rules.